SecBot SecBot
Insider Cluster (2 insiders) ·Filed Aug 5, 2026

PCVX

Vaxcyte, Inc.
NEUTRAL
Impact 2/10
Horizonimmediate Processed3mo ago
Insider cluster: 2 insiders, $395K total
Actionable Insight • Neutral

This insider cluster is too small to warrant a trading signal. Monitor for any larger, unplanned open-market sales from C-suite executives, which would be more informative. The company's next pipeline catalyst (likely VAX-24 Phase 3 data) remains the primary driver for the stock.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$58.89
T+0 close · Aug 5, 2026 · via day close
Latest settled
+6.32%
T+60 · $62.61
Vs SPY
+7.74%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 6 $58.89entry
  2. T+1 · 3mo ago −1.39%α −2.00% · $58.07
  3. T+5 · 3mo ago −0.05%α −1.26% · $58.86
  4. T+20 · 3mo ago +3.87%α +3.27% · $61.17
  5. T+60 · 18d ago +6.32%α +7.74% · $62.61
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Two top executives at Vaxcyte, the CEO and CFO, sold a combined $395K in open-market stock over a one-week window, with the CFO's sale following a derivative exercise. The total dollar value is only ~0.005% of the $8.1B market cap, making this a routine, immaterial cluster. No insider buying occurred, and the sales are consistent with standard post-vesting diversification, not a bearish signal on the company's pipeline or prospects.

Key Financial Metrics

Direction
selling
Total Value
$395.0K
Insiders
2

Key Facts

  • CEO Grant Pickering sold 378 shares for ~$21K on 2026-07-27.
  • CFO Andrew Guggenhime sold ~10,000 shares total for ~$374K on 2026-08-03, following derivative exercises.
  • Total open-market sales of ~$395K represent ~0.005% of Vaxcyte's $8.1B market cap.
  • No insider purchases were made during the cluster window.
  • The cluster is small in both absolute and relative terms, consistent with routine portfolio management.

Financial Impact

Total insider sales of ~$395K, or ~0.005% of market cap, trivial and non-material.

insider ownership

Risk Factors

  • No bearish signal from this cluster; the stock remains driven by clinical trial outcomes.
  • If future insider selling accelerates beyond routine vesting-related transactions, it could signal reduced confidence.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
88% bullish (17 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-PCVX-1786003639690

US Market Status

Market Closed · Opens Wed (14h 25m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 6, 2026